<p>周一，Summit 治疗股价上涨了 0.8%。该公司股价最高达到 22.17 美元，最后交易价为 21.39 美元。交易中约有 592,087 股换手，较平均每日成交量 3,717,354 股下降了 84%。该股上一个收盘价为 21.21 美元。</p>
<p>获取 <strong>Summit 治疗</strong> 警报：</p>
<h2>分析师评级</h2>
<ul>
<li>Summit 治疗因试验结果大涨：是时候买入了吗？</li>
</ul>
<p>一些研究分析师最近对 SMMT 股票发表了意见。HC Wainwright 在 10 月 4 日星期五的报告中重申了对 Summit 治疗股票的 “买入” 评级，并设定了 45.00 美元的目标价。Stifel Nicolaus 在 9 月 25 日星期三的报告中将他们对 Summit 治疗股票的目标价从 25.00 美元上调至 40.00 美元，并给予了 “买入” 评级。最后，花旗集团在 9 月 27 日星期五的报告中将对 Summit 治疗股票的评级从 “买入” 调降至 “中性”，并将目标价从 19.00 美元上调至 23.00 美元。</p>
<p>获取我们对 Summit 治疗的最新股票报告</p>
<h2>Summit 治疗股价下跌 3.5%</h2>
<p>该公司的五十日移动平均线为 18.34 美元，两百日移动平均线为 10.82 美元。</p>
<p>Summit 治疗（NASDAQ:SMMT - 获取免费报告）最近公布了其截至 8 月 6 日星期二的财报。该公司本季度每股亏损 0.05 美元，超过了每股亏损 0.06 美元的共识预期 0.01 美元。分析师平均预计，Summit 治疗公司本财年每股盈利为-0.27 美元。</p>
<h2>Summit 治疗的机构交易</h2>
<p>对该股票进行了买卖的对冲基金和其他机构投资者。Griffin Asset Management Inc.在第三季度以 148.4 万美元的价格获得了 Summit 治疗的新股份。Millennium Management LLC 在第二季度以约 1515.4 万美元的价格购入了 Summit 治疗的新头寸。Mirae Asset Global Investments Co. Ltd.在第一季度将其对 Summit 治疗的持股比例提高了 131.3%。Mirae Asset Global Investments Co. Ltd.现在拥有该公司股票的 40,476 股，价值 168,000 美元，较上一季度增持了 22,977 股。SG Americas Securities LLC 在第三季度以约 71.7 万美元的价格购入了 Summit 治疗的新头寸。最后，Squarepoint Ops LLC 在第二季度将其对 Summit 治疗的持股比例提高了 192.2%。Squarepoint Ops LLC 现在拥有该公司股票的 86,064 股，价值 671,000 美元，较上一季度增持了 56,614 股。目前有 4.61% 的股份由机构投资者和对冲基金持有。</p>
<h2>Summit 治疗公司简介（获取免费报告）</h2>
<p>Summit 治疗公司是一家生物制药公司，专注于在美国和英国发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法。该公司的主要开发候选药物是 Ivonescimab，一种通过 PD-1 阻断和抗血管生成作用进行免疫疗法的双特异性抗体；抗感染组合包括 SMT-738，一种用于治疗多药耐药感染的新型精准抗生素，主要包括碳青霉烯耐药肠杆菌感染。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票比 Summit 治疗更好</li>
<li>如何计算投资回报率（ROI）</li>
<li>分析师预测网络安全股票将在圣诞节前创新高</li>
<li>CD 计算器：定期存款计算器</li>
<li>核能达到临界质量：现在关注的热门股票</li>
<li>股票中的跳空意味着什么？如何把握这个跳空</li>
<li>两家能源公司因获得十亿美元的能源部贷款承诺而大涨</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 查尔斯·佩恩希望您为第四季度做好准备（来自不可阻挡的繁荣）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Summit 治疗股票？</h2>
<p>在考虑购买 Summit 治疗股票之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Summit 治疗并不在名单上。</p>
<p>尽管 Summit 治疗目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Summit治疗

<p>Summit 治疗（NASDAQ:SMMT）看到其股价上涨了 0.8%，达到 0.39 美元，成交量为 592,087 股，远低于其平均交易量。分析师对此持有不同观点：HC Wainwright 维持 “买入” 评级，目标价为 0.00 美元，而花旗集团将其降级为 “中性”。该公司报告的每股收益为-0.05 美元，超过了预期。机构投资者增加了持股比例，持有该股的 4.61%。Summit 专注于开发多药耐药感染和免疫疗法的治疗方案</p>

<p>Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report)'s share price was up 0.8% on Monday . The company traded as high as $22.17 and last traded at $21.39. Approximately 592,087 shares changed hands during trading, a decline of 84% from the average daily volume of 3,717,354 shares. The stock had previously closed at $21.21.</p>
<div class="lb-trans"><p>周一，Summit 治疗股价上涨了 0.8%。该公司股价最高达到 22.17 美元，最后交易价为 21.39 美元。交易中约有 592,087 股换手，较平均每日成交量 3,717,354 股下降了 84%。该股上一个收盘价为 21.21 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Summit 治疗</strong> 警报：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<ul>
<li>Summit Therapeutics Surges on Trial Results: Time to Buy?</li>
</ul>
<div class="lb-trans"><h2>分析师评级</h2>
<ul>
<li>Summit 治疗因试验结果大涨：是时候买入了吗？</li>
</ul>
</div><p>A number of research analysts have recently weighed in on SMMT shares. HC Wainwright restated a &#34;buy&#34; rating and set a $45.00 price target on shares of Summit Therapeutics in a report on Friday, October 4th. Stifel Nicolaus lifted their target price on shares of Summit Therapeutics from $25.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, September 25th. Finally, Citigroup downgraded shares of Summit Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lifted their target price for the stock from $19.00 to $23.00 in a report on Friday, September 27th.</p>
<div class="lb-trans"><p>一些研究分析师最近对 SMMT 股票发表了意见。HC Wainwright 在 10 月 4 日星期五的报告中重申了对 Summit 治疗股票的 “买入” 评级，并设定了 45.00 美元的目标价。Stifel Nicolaus 在 9 月 25 日星期三的报告中将他们对 Summit 治疗股票的目标价从 25.00 美元上调至 40.00 美元，并给予了 “买入” 评级。最后，花旗集团在 9 月 27 日星期五的报告中将对 Summit 治疗股票的评级从 “买入” 调降至 “中性”，并将目标价从 19.00 美元上调至 23.00 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Summit Therapeutics</strong></p>
<div class="lb-trans"><p>获取我们对 Summit 治疗的最新股票报告</p>
</div><h2>Summit Therapeutics Stock Down 3.5 %</h2>
<div class="lb-trans"><h2>Summit 治疗股价下跌 3.5%</h2>
</div><p>The firm's fifty day moving average is $18.34 and its 200 day moving average is $10.82.</p>
<div class="lb-trans"><p>该公司的五十日移动平均线为 18.34 美元，两百日移动平均线为 10.82 美元。</p>
</div><p>Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect that Summit Therapeutics Inc. will post -0.27 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Summit 治疗（NASDAQ:SMMT - 获取免费报告）最近公布了其截至 8 月 6 日星期二的财报。该公司本季度每股亏损 0.05 美元，超过了每股亏损 0.06 美元的共识预期 0.01 美元。分析师平均预计，Summit 治疗公司本财年每股盈利为-0.27 美元。</p>
</div><h2>Institutional Trading of Summit Therapeutics</h2>
<div class="lb-trans"><h2>Summit 治疗的机构交易</h2>
</div><p>Hedge funds and other institutional investors have recently bought and sold shares of the stock. Griffin Asset Management Inc. acquired a new stake in Summit Therapeutics in the 3rd quarter worth $1,484,000. Millennium Management LLC bought a new position in shares of Summit Therapeutics in the second quarter worth about $15,154,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Summit Therapeutics by 131.3% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,476 shares of the company's stock worth $168,000 after buying an additional 22,977 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Summit Therapeutics during the third quarter worth approximately $717,000. Finally, Squarepoint Ops LLC raised its stake in shares of Summit Therapeutics by 192.2% during the second quarter. Squarepoint Ops LLC now owns 86,064 shares of the company's stock worth $671,000 after buying an additional 56,614 shares during the last quarter. 4.61% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>对该股票进行了买卖的对冲基金和其他机构投资者。Griffin Asset Management Inc.在第三季度以 148.4 万美元的价格获得了 Summit 治疗的新股份。Millennium Management LLC 在第二季度以约 1515.4 万美元的价格购入了 Summit 治疗的新头寸。Mirae Asset Global Investments Co. Ltd.在第一季度将其对 Summit 治疗的持股比例提高了 131.3%。Mirae Asset Global Investments Co. Ltd.现在拥有该公司股票的 40,476 股，价值 168,000 美元，较上一季度增持了 22,977 股。SG Americas Securities LLC 在第三季度以约 71.7 万美元的价格购入了 Summit 治疗的新头寸。最后，Squarepoint Ops LLC 在第二季度将其对 Summit 治疗的持股比例提高了 192.2%。Squarepoint Ops LLC 现在拥有该公司股票的 86,064 股，价值 671,000 美元，较上一季度增持了 56,614 股。目前有 4.61% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Summit Therapeutics Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Summit 治疗公司简介（获取免费报告）</h2>
</div><p>Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.</p>
<div class="lb-trans"><p>Summit 治疗公司是一家生物制药公司，专注于在美国和英国发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法。该公司的主要开发候选药物是 Ivonescimab，一种通过 PD-1 阻断和抗血管生成作用进行免疫疗法的双特异性抗体；抗感染组合包括 SMT-738，一种用于治疗多药耐药感染的新型精准抗生素，主要包括碳青霉烯耐药肠杆菌感染。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Analysts Predict New Highs for Cybersecurity Stock by Christmas</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票比 Summit 治疗更好</li>
<li>如何计算投资回报率（ROI）</li>
<li>分析师预测网络安全股票将在圣诞节前创新高</li>
<li>CD 计算器：定期存款计算器</li>
<li>核能达到临界质量：现在关注的热门股票</li>
<li>股票中的跳空意味着什么？如何把握这个跳空</li>
<li>两家能源公司因获得十亿美元的能源部贷款承诺而大涨</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的财务数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Charles Payne Wants You Prepared for Q4 (From Unstoppable Prosperity)(Ad)</p>
<div class="lb-trans"><p>→ 查尔斯·佩恩希望您为第四季度做好准备（来自不可阻挡的繁荣）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05OTU4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9958&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Summit Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Summit 治疗股票？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Summit 治疗股票之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Summit 治疗并不在名单上。</p>
</div><p>While Summit Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Summit 治疗目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Summit 治疗公司（纳斯达克代码：SMMT）股价上涨 0.8% - 事件详情如下